The Latest Cardiac and Vascular News
BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in […]
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024.
EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model
September 16, 2024 07:01 PM Eastern Daylight Time NYON, Switzerland–(BUSINESS WIRE)–Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, expanding minimally invasive treatment options to a broader range of patients with congenital heart conditions. “I am proud […]
September 17, 2024 07:47 AM Eastern Daylight Time LAUSANNE, Switzerland–(BUSINESS WIRE)–Novostia, a pioneering medical technology company, specializing in the development of a disruptive heart valve prosthesis, at clinical stage, today announces a leadership transition alongside the successful completion of a CHF 5.6 million fund raise to further accelerate the company’s […]
DUBLIN–(BUSINESS WIRE)–The “XARELTO Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. “XARELTO Market Size, Forecast, and Market Insight – 2032” Post this The latest industry report provides a thorough analysis of the potential growth and impact of XARELTO for the treatment of Peripheral Artery Disease (PAD) in […]
September 17, 2024 12:09 PM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–The “ZONTIVITY Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. “ZONTIVITY Market Size, Forecast, and Market Insight – 2032” Post this ZONTIVITY, known for its efficacy in reducing thrombotic cardiovascular events, emerges as a significant pharmaceutical agent in […]
*** September is National Atrial Fibrillation Awareness Month *** SAN FRANCISCO, Sept. 17, 2024 /PRNewswire/ — BACKGROUND: We all know someone who’s had a heart scare – an unusual flutter or disconcerting palpitations. The potential cause? A little-known and often silent heart health…
WASHINGTON, Sept. 17, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) Board of Directors has named Anuradha Lala-Trindade, MD and Robert J. Mentz, MD as Co-Editors-in-Chief of the Journal of Cardiac Failure, the official journal of HFSA and the Japanese Heart Failure…
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the 160cm FDA approved version of its unique LumiGuide endovascular navigation wire. This enhanced LumiGuide guidewire, which utilizes the company’s breakthrough Fiber Optic RealShape (FORS) technology, was used for the first time on a patient by Professor and vascular surgeon Carlos Timaran, MD, an internationally recognized expert in advanced endovascular techniques. He used the technology during a complex aortic aneurism repair operation, marking the 1000th patient treated milestone using FORS technology since first clinical use of the technology in 2020. The introduction of a longer FORS-enabled LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters and expands usage of this technology to patients in America treated in centers equipped with LumiGuide.
